Impact of Severe Hepatic Impairment on Pharmacokinetics of Cenicriviroc and Its Metabolites

Summary

The objective of this study is to assess the pharmacokinetics (PK), safety, and tolerability profiles of cenicriviroc (CVC) and its metabolites (M-I and M-II) in participants with severely impaired hepatic function compared with matched healthy participants following single-dose administration

Timeline

Start

2017-06-06

Primary completion

2017-11-24

Completion

2017-12-17

Drugs

Indications